Latest news with #CollPlant
Yahoo
05-08-2025
- Business
- Yahoo
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS
REHOVOT, Israel, Aug. 5, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the second quarter on Wednesday, August 20, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit Contacts: CollPlant:Eran RotemDeputy CEO & CFOTel: +972-73-2325600Email: eran@ Investors:Daniel FerryManaging DirectorLifeSci Advisors, LLCdaniel@ Logo: View original content: SOURCE CollPlant Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
14-07-2025
- Business
- Yahoo
CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations
New U.S.-based role to support growth strategy, partnerships, and scaling of rhCollagen product platforms REHOVOT, Israel, July 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen), today announced the appointment of Bowman Bagley as Vice President, Commercial North America. In this newly created role, Mr. Bagley will lead the company's commercial strategy and execution in North America, including sales and marketing, logistics, and expansion of market presence for CollPlant's rhCollagen-based products and platforms. "We are excited to welcome Bowman to the CollPlant leadership team as we scale our commercial operations and development programs," said Yehiel Tal, Chief Executive Officer of CollPlant. "His deep expertise in collagen-based biomaterials, 3D bioprinting, and tissue engineering aligns perfectly with our growth strategy. Bowman's proven track record in sales, product development, licensing, and operational execution will be instrumental as we grow our bioinks portfolio and expand rhCollagen sales to the research market as well as to strategic collaborators in the fields of regenerative and aesthetic medicine." Mr. Bagley joins CollPlant from Wasatch Biolabs, a genomics research company, where he served as Vice President and Fractional CxO, leading revenue operations and growth initiatives. Previously, he spent nearly a decade at Advanced BioMatrix, a global supplier of purified collagen and extracellular matrix products, where he served as Chief Executive Officer. During his tenure, he held leadership roles across product development, business development, and global sales, helping to establish the company as a leading supplier in the research and tissue engineering space. In addition to his leadership roles, Mr. Bagley has advised life science companies on go-to-market strategies, commercial partnerships, and scaling operations. He is also an active angel investor with NuFund Venture Group, where he conducts due diligence on emerging biotech ventures. "I am honored to join CollPlant at such an exciting time in its growth trajectory," said Bowman Bagley. "CollPlant's recombinant human collagen platform represents a transformative advancement in regenerative medicine and biomaterials. I'm eager to contribute to the company's mission and help accelerate the commercial success of its innovative product portfolio, while driving long-term value for shareholders." Mr. Bagley holds a B.S. in Neuroscience from Brigham Young University and an MBA from the University of Utah. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit Forward-Looking Statements This press release includes forward-looking statements. Forward-looking statements include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company's preferences regarding such methods, and including its ability to conclude a non-dilutive financing transaction; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel, projected capital expenditures and liquidity, changes in the Company's strategy and development plans and projects, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts CollPlant:Eran RotemDeputy CEO & CFO+ 972-73-2325600Eran@ Investors:LifeSci AdvisorsDan Ferrydaniel@ Photo - - View original content to download multimedia: SOURCE CollPlant
Yahoo
30-05-2025
- Business
- Yahoo
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
REHOVOT, Israel, May 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,200,002 of the Company's ordinary shares at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company's ordinary shares at an exercise price of $3.00 per share. The warrants will be exercisable immediately following the issuance date and have a term of three and one-half years from the issuance date. The offering is expected to close on or about June 2, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Yehiel Tal, CollPlant's Chief Executive Officer, commented, "We believe the additional capital will help shore up our balance sheet and provide us with additional flexibility to execute on our business plan. We remain committed to creating long-term value for our shareholders as we advance our mission to be a leader in the regenerative and aesthetic medicine space." The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be approximately $3.6 million. CollPlant intends to use the net proceeds for general corporate purposes, which may include but are not limited to, supporting the work with its business partner, AbbVie, regarding the dermal filler product candidate, working capital and funding its research and development programs. The ordinary shares (but not the warrants issued in the private placement or the ordinary shares underlying such warrants) are being offered by CollPlant pursuant to a "shelf" registration statement on Form F-3 (File No. 333-269087) originally filed with the U.S. Securities and Exchange Commission (the "SEC") on December 20, 2022 and declared effective by the SEC on January 10, 2023. The ordinary shares to be issued in the registered direct offering are being offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to, and describing the terms of, the registered direct offering will be filed with the SEC and will be available on the SEC's website located at Electronic copies of the final prospectus supplement and the accompanying base prospectus relating to the registered direct offering, when available, may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@ The warrants described above are being issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder and, along with the ordinary shares underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying ordinary shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit Forward-Looking Statements This press release includes forward-looking statements. Forward-looking statements include, but are not limited to, statements relating to the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering, the intended use of proceeds from the registered direct offering, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company's preferences regarding such methods, and including its ability to conclude a non-dilutive financing transaction; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in Israel, projected capital expenditures and liquidity, changes in the Company's strategy and development plans and projects, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant are contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts CollPlant:Eran RotemDeputy CEO & CFO+ 972-73-2325600Eran@ Investors:LifeSci AdvisorsDan Ferrydaniel@ Logo: View original content: SOURCE CollPlant Sign in to access your portfolio
Yahoo
14-05-2025
- Business
- Yahoo
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS
REHOVOT, Israel, May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. For more information about CollPlant, visit Contacts:CollPlant:Eran RotemDeputy CEO & CFOTel: +972-73-2325600Email: eran@ FerryManaging DirectorLifeSci Advisors, LLCdaniel@ Logo: View original content: SOURCE CollPlant Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-03-2025
- Business
- Yahoo
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...
Q4 2024 Revenue: $164,000, down from $299,000 in Q4 2023. Full Year 2024 Revenue: $515,000, down from $11 million in 2023. Q4 2024 Cost of Revenue: $272,000, down from $773,000 in Q4 2023. Full Year 2024 Cost of Revenue: $1.6 million, down from $2 million in 2023. Q4 2024 Gross Loss: $108,000, compared to $474,000 in Q4 2023. Full Year 2024 Gross Loss: $1.1 million, compared to a gross profit of $9 million in 2023. Q4 2024 Operating Expenses: $3.9 million, down from $4.6 million in Q4 2023. Full Year 2024 Operating Expenses: $16.1 million, down from $16.5 million in 2023. Q4 2024 Net Loss: $3.9 million or $0.34 per share, compared to $4.7 million or $0.41 per share in Q4 2023. Full Year 2024 Net Loss: $16.6 million or $1.45 per share, compared to $7 million or $0.62 per share in 2023. Cash and Cash Equivalents (Dec 31, 2024): $11.9 million. Cash Used in Operating Activities (2024): $14.1 million, compared to $2.8 million in 2023. Cash Used in Investing Activities (2024): $539,000, compared to $1.2 million provided in 2023. Cash Provided by Financing Activities (2024): $9,000, compared to $1.1 million in 2023. Warning! GuruFocus has detected 4 Warning Signs with CLGN. Release Date: March 26, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. CollPlant Biotechnologies Ltd (NASDAQ:CLGN) is advancing its proprietary photocurable dermal filler, which is in the preclinical phase and targets a market valued at approximately $6.3 billion with a 10% compound annual growth rate. The company has received positive feedback from thought leaders in aesthetic medicine regarding its photocurable dermal filler, suggesting it could be a game changer for facial plastic surgery. CollPlant's collaboration with AbbVie is progressing, with AbbVie collecting data from clinical trials and a recent $2 million payment received by CollPlant following a development achievement. The regenerative breast implant program is showing promising preclinical results, with successful tissue integration and vascularization observed in one study arm. CollPlant's recombinant human collagen technology is in demand, with ongoing discussions with various companies interested in accessing this technology. CollPlant Biotechnologies Ltd (NASDAQ:CLGN) reported a significant decrease in GAAP revenues for 2024, with $515,000 compared to $11 million in 2023, primarily due to a $10 million milestone payment from AbbVie in 2023. The company experienced a GAAP gross loss of $1.1 million for the year ended December 31, 2024, compared to a gross profit of $9 million in 2023. GAAP net loss for 2024 was $16.6 million, significantly higher than the $7 million net loss in 2023, attributed to the absence of a large milestone payment received in the previous year. Cash used in operating activities increased to $14.1 million in 2024 from $2.8 million in 2023, indicating higher operational expenses. The company's cash runway is expected to last only until the second quarter of 2026, raising concerns about long-term financial sustainability without additional revenue streams or partnerships. Q: When can we expect an update from AbbVie on their studies, and are there any anticipated milestone payments in 2025? A: AbbVie is currently reviewing interim results from the first cohort of patients in their dermal filler clinical trials. The next steps will be determined by AbbVie, and we will update the market accordingly. Recently, we received a $2 million payment from AbbVie following a development achievement, but we cannot estimate when the next milestone payment will occur. - Eran Rotem, Deputy CEO and CFO Q: Can you provide details on the market potential and revenue expectations for the VergenixSTR product in Europe and Asia? A: VergenixSTR is intended for treating tendinopathy and has a market potential of 1% to 3% of the population. We are establishing a distribution network in Europe and Asia, and each country requires regulatory approval. We expect to start seeing sales next year, with the product offering a significant advantage over steroid injections. - Yehiel Tal, CEO Q: What is the company's current cash position and burn rate, and how long will it last? A: As of December 31, 2024, we had $11.9 million in cash, not including a recent $2 million payment from AbbVie. Our cost reduction plan does not materially impact main development programs. We expect our cash to support operations through the second quarter of 2026, under conservative assumptions. - Eran Rotem, Deputy CEO and CFO Q: What are the upcoming catalysts for CollPlant's proprietary programs? A: We plan to potentially launch a clinical trial for our photocurable dermal and soft tissue filler within two years. For our regenerative breast implant program, we aim to optimize the implant characteristics and clinical protocol to reach clinical trial readiness. We will also expand the distribution network for VergenixSTR in Europe and Asia and broaden our bioinks product offerings. - Yehiel Tal, CEO Q: How is CollPlant planning to expand sales of its rhCollagen product? A: We plan to expand sales of our rhCollagen to selected customers that align with our business model. This expansion is part of our strategy to support various bioprinting technologies and advance potential partnership discussions. - Yehiel Tal, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
